AKT1 and Hyperglycemia: The Akt inhibitors currently in clinical trials are pan-Akt inhibitors that inhibit the different Akt isoforms to a similar extent; however, these pan-Akt inhibitors exert undesired side effects, such as hyperglycemia, hyperinsulinemia, and diabetes (Wang et al., 2017).